33786-93-5

Basic information

• Product Name: 3,5-DIAMINOBENZONITRILE
• Synonyms: 3,5-Diaminobenzonitrile 97%
• CAS NO: 33786-93-5
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15
• Product Categories: C6 to C7;Cyanides/Nitriles;Nitrogen Compounds
• Mol File: 33786-93-5.mol

Chemical Properties

• Melting Point: 188-191 °C
• Boiling Point: 405.506°C at 760 mmHg
• Flash Point: 199.043°C
• Appearance: /
• Density: 1.245g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.64
• CAS DataBase Reference: 3,5-DIAMINOBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIAMINOBENZONITRILE(33786-93-5)
• EPA Substance Registry System: 3,5-DIAMINOBENZONITRILE(33786-93-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 33786-93-5(Hazardous Substances Data)

Usage

Uses

Used in Dye and Pigment Production:
3,5-Diaminobenzonitrile is used as a key intermediate in the synthesis of various dyes and pigments. Its unique chemical structure contributes to the color properties and stability of the final products, making it an important component in this industry.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 3,5-Diaminobenzonitrile serves as a crucial intermediate for the production of certain drugs. Its reactivity and functional groups make it a versatile building block in the synthesis of a range of pharmaceutical compounds.
Used in Organic Compound Synthesis:
3,5-Diaminobenzonitrile is also utilized as an intermediate in the synthesis of other organic compounds. Its presence in various chemical reactions allows for the creation of a wide array of products, highlighting its importance in organic chemistry.
Safety Precautions:
Given its potential to cause skin and eye irritation, it is imperative to handle 3,5-Diaminobenzonitrile with care. Proper protective equipment, such as gloves and safety goggles, should be worn during its use. Additionally, it is essential to follow established safety protocols and guidelines to minimize potential hazards in both industrial and laboratory settings.

InChI:InChI=1/C7H7N3/c8-4-5-1-6(9)3-7(10)2-5/h1-3H,9-10H2

Upstream product

• 4110-35-4 3,5-dinitrobenzonitrile 
• 55215-57-1 1-amino-3-bromo-5-nitrobenzene 
• 535-87-5 3.5-diaminobenzoic acid 
• 53882-15-8 3,5-diaminobenzamide 

Downstream Products

• 53882-11-4 diethyl N,N'-(5-cyano-m-phenylene)dioxamate 
• 53882-15-8 3,5-diaminobenzamide 
• 1445879-67-3 4-((3-amino-5-cyanophenyl)amino)-N-cyclopropyl-7-(2,4-dimethoxypyrimidin-5-yl)quinoline-3-sulfonamide 
• 1394805-68-5 (R)-N-{1-[2-(3-amino-5-cyanophenylamino)-6-propylpyrimidin-4-yl]piperidin-3-yl}-2-hydroxyacetamide hydrochloride 
• 1394318-58-1 (S)-3-amino-5-{[4-(3-aminopyrrolidin-1-yl)-6-propylpyrimidin-2-yl]amino}benzonitrile 
• 1312291-17-0 3-[(7-chloroquinolin-4-yl)amino]-5-{[2-(piperidin-1-yl)ethyl]amino}benzonitrile 
• 1312291-14-7 4-[(3-amino-5-cyanophenyl)amino]-7-chloro-1-[2-(piperidin-1-yl)ethyl]quinolin-1-ium chloride 
• 1312291-13-6 3-amino-5-[(7-chloroquinolin-4-yl)amino]benzonitrile hydrochloride 
• 1312291-18-1 3-amino-5-{[2-(piperidin-1-yl)ethyl]amino}benzonitrile 
• 918810-59-0 N-(3-Acetylamino-5-cyano-phenyl)-acetamide 
• 53882-10-3 N,n'-(5-cyano-m-phenylene)dioxamic acid 

Relevant articles and documents

SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure (I) wherein RN, R1, R2, R3, R4, L,V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, X, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

Corresponding amine nitrile and method of manufacturing thereof

The invention relates to a manufacturing method of nitrile. Compared with the prior art, the manufacturing method has the characteristics of significantly reduced using amount of an ammonia source, low environmental pressure, low energy consumption, low production cost, high purity and yield of a nitrile product and the like, and nitrile with a more complex structure can be obtained. The invention also relates to a method for manufacturing corresponding amine from nitrile.

7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

NOVEL AMIDE COMPOUNDS

A compound of the formula (I):R1-A-X-NHCO-Y-R2 ???whereinR1 is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents,R2 is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents,A is a group of the formula:-(CH2)t-(O)m- or in which R3 and R4 are each hydrogen or linked together to form imino,R5 is hydrogen or lower alkyl,t is 0, 1 or 2,p, m and n are each 0 or 1,X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents,Y is bond, lower alkylene, or lower alkenylene, and a salt thereof.

Anxiolytic activity of analogues of 4-benzylamino-2-methyl-7H- pyrrolo[2,3-d]pyrimidines

An extensive series of analogues of the lead anxiolytic 4-benzylamino- 2-methylpyrrolo[2,3-d]pyrimidine 1 was synthesized and evaluated in the Geller-Seifter conflict test for anxiolytic activity to discover a less toxic derivative. Analysis of the SAR revealed that the most potent compounds were those with meta substituents on the benzylamino ring. In this group the most promising derivatives were 4-[bis(3,5-dimethylamino)]benzylamino-2-methyl- 7H-pyrrolo[2,3-d]pyrimidine 12 and 4-(3,5-dimethylbenzylamino)-2-methyl-7H- pyrrolo[2,3-d]pyrimidine 24. Potential metabolites of 12 were synthesized and checked for their anxiolytic activity. Less toxic analogues of the second lead 24 were prepared by extending the alkyl groups attached to the benzene ring moiety. The addition of a fluoro substituent to the benzene moiety in the extended alkyl chain analogue 4-(3,5-diethyl-2-fluorobenzylamino)2- methyl-7H-pyrrolo[2,3-d]pyrimidine 34 resulted in a compound with a longer duration of activity relative to its analogue 4-(3,5-diethylbenzylamino)-2- methyl-7H-pyrrolo[2,3-d]pyrimidine 26.

Cyano phenylene dioxamic molecules

Compounds represented below SPC1 And pharmaceutical compositions thereof, the compositions including the non-substituted phenylene dioxamates are useful in the prophylactic treatment of sensitized mammals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature.